BRCA2 and cancer: In this same context, Lavie et al. (2011) showed that a 1.85% prevalence of BRCA1 and BRCA2 DH in Ashkenazi Jewish patients with FA-D1 have a distinctively higher risk of specific cancers than patients in other Fanconi anemia complementation groups.